Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$170.74 USD

170.74
7,933,856

-0.30 (-0.18%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $171.12 +0.38 (0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sridatri Sarkar headshot

3 AI-Driven Medical Device Stocks to Watch in 2025

by Sridatri Sarkar

BSX, JNJ and GEHC are leveraging AI to boost device performance, diagnostics and surgical precision in 2025.

Ekta Bagri headshot

Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump

by Ekta Bagri

Trump revives tariff threats on pharma imports, but industry giants like LLY and JNJ stay unfazed with major U.S. investments underway.

Moumi Mondal headshot

Hologic's GYN Surgical Dominance: What's Powering the Road Ahead?

by Moumi Mondal

HOLX's GYN Surgical arm gains momentum with Fluent Pro, global expansion and strategic acquisitions fueling growth.

Zacks Equity Research

Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Kanishka Das headshot

Merck Faces Multiple Challenges: Will It Steer Through Successfully?

by Kanishka Das

MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.

Kinjel Shah headshot

JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?

by Kinjel Shah

JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.

Zacks Equity Research

Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks

by Zacks Equity Research

GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.

Sundeep Ganoria headshot

How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?

by Sundeep Ganoria

ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.

Zacks Equity Research

Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Kinjel Shah headshot

Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales?

by Kinjel Shah

JNJ's MedTech unit eyes second-half growth despite China headwinds, U.S. competition and tariff pressure.

Zacks Equity Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Equity Research

Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again

by Zacks Equity Research

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Johnson & Johnson (JNJ) Could Be a Great Choice

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Zacks Equity Research

The Zacks Analyst Blog Highlights Johnson & Johnson, The Home Depot, Micron Technology, Autoscope Technologies and Nova LifeStyle

by Zacks Equity Research

JNJ, HD, MU, AATC, and NVFY stand out with strong gains and strategic shifts amid macro headwinds and evolving consumer demand.

Zacks Equity Research

Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?

by Zacks Equity Research

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Kanishka Das headshot

MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE

by Kanishka Das

Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.

Mark Vickery headshot

Top Analyst Reports for Johnson & Johnson, Home Depot and Micron

by Mark Vickery

MU gains 42.5% YTD as AI demand fuels DRAM growth, while JNJ and HD navigate pricing, pipeline, and macro headwinds.

Kinjel Shah headshot

Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?

by Kinjel Shah

JNJ is banking on Darzalex, Tremfya and new drugs to offset Stelara's LOE and Part D headwinds in Q2 Innovative Medicine sales.

Zacks Equity Research

Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts

by Zacks Equity Research

Johnson & Johnson (JNJ) concluded the recent trading session at $155.92, signifying a +2.08% move from its prior day's close.

Zacks Equity Research

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

Zacks Equity Research

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Zacks Equity Research

Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for HDV

Kinjel Shah headshot

J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?

by Kinjel Shah

JNJ's MedTech sales face pressure from China and competition but new products may lead to a stronger second half of 2025.

Zacks Equity Research

MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal

by Zacks Equity Research

Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.